-
Mashup Score: 1
AbstractAims. The aim of this study was to evaluate the efficacy and safety of prasugrel dose de-escalation therapy in patients with diabetes mellitus (DM)–acut
Source: academic.oup.comCategories: Cardiologists, Latest HeadlinesTweet
-
Mashup Score: 10Comparison of bleeding risk between standard ticagrelor and prasugrel therapies without de-escalation strategy - 9 month(s) ago
This commentary refers to ‘Dual antiplatelet therapy de-escalation in acute coronary syndrome: an individual patient meta-analysis’ by J. Kang et al., 2023, htt
Source: academic.oup.comCategories: Cardiologists, Latest HeadlinesTweet
-
Mashup Score: 34Ticagrelor vs Prasugrel in a Contemporary Real-World Cohort Undergoing Percutaneous Coronary Intervention: - 1 year(s) ago
Abstract Background Potent P2Y12 agents such as ticagrelor and prasugrel are increasingly utilized across the clinical spectrum of patients undergoing percutaneous coronary intervention (PCI). Ther…
Categories: Expert Picks, Latest HeadlinesTweet
-
Mashup Score: 2Body mass index and efficacy and safety of ticagrelor versus prasugrel in patients with acute coronary syndromes - PubMed - 2 year(s) ago
NCT01944800.
Source: PubMedCategories: Cardiologists, Latest HeadlinesTweet
-
Mashup Score: 2Influence of body size on platelet response to ticagrelor and prasugrel in patients with acute coronary syndromes - PubMed - 2 year(s) ago
Influence of body size on platelet response to ticagrelor and prasugrel in patients with acute coronary syndromes
Source: PubMedCategories: Cardiologists, Latest HeadlinesTweet
-
Mashup Score: 0
This post hoc analysis investigates whether the benefits of prasugrel dose de-escalation therapy are maintained in the complex percutaneous coronary intervention subgroup.
Source: jamanetwork.comCategories: Cardiologists, Latest HeadlinesTweet
-
Mashup Score: 1
This post hoc analysis investigates whether the benefits of prasugrel dose de-escalation therapy are maintained in the complex percutaneous coronary intervention subgroup.
Source: jamanetwork.comCategories: Cardiologists, Latest HeadlinesTweet-
#Prasugrel Dose De-escalation Therapy After Complex PCI in Patients With #ACS A Post Hoc Analysis From the HOST-REDUCE-POLYTECH-ACS Trial Prasugrel dose de-escalation was not associated with an increased risk of ischemic outcomes https://t.co/Clo25fbPZI @JAMA_current @JAMACardio https://t.co/X5FOQNtOU7
-
-
Mashup Score: 24Meta-Analysis Comparing the Safety and Efficacy of Prasugrel and Ticagrelor in Acute Coronary Syndrome - 2 year(s) ago
Prasugrel and ticagrelor are preferred over clopidogrel for patients with acute coronary syndrome who underwent percutaneous coronary intervention. We sought to determine the relative merits of 1 agent over the other. Multiple databases were queried to identify relevant randomized control trials (RCTs) and observational cohort studies. Random-effects model was used to calculate an unadjusted odds…
Source: American Journal of CardiologyCategories: Cardiologists, Latest HeadlinesTweet
-
Mashup Score: 10Comparison of Prasugrel and Ticagrelor for Patients with Acute Coronary Syndrome: A Systematic Review and Meta-analysis - PubMed - 2 year(s) ago
Of the 11 eligible RCTs with 6098 patients randomized to prasugrel (n=3050) or ticagrelor (n=3048), 180 and 207 had the composite endpoint events in the prasugrel arm and the ticagrelor arm respectively over a weighted mean follow up period of 11±2 months. Compared with prasugrel, the ticagrelor gro …
Source: PubMedCategories: Cardiologists, Latest HeadlinesTweet
-
Mashup Score: 3NSTE-ACS ESC Guidelines Recommend Prasugrel as the Preferred P2Y12 Inhibitor: A Contrarian View - 2 year(s) ago
In the 2020 European Society of Cardiology guidelines on non-ST-segment elevation acute coronary syndromes (NSTE-ACS), the experts proposed to put an end to the equipoise of ticagrelor and prasugrel in addition to aspirin in patients with NSTE-ACS who …
Source: PubMed Central (PMC)Categories: Cardiologists, Latest HeadlinesTweet
Is #DAPT for 12 months the optimal strategy ? #Prasugrel dose de-escalation in diabetic patients with #ACS #PCI HOST-REDUCE-POLYTECH-ACS trial https://t.co/SW2bejPbgy